MGM Resorts vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Las Vegas gaming and hospitality (NYSE: MGM) at record $17.24B 2024 revenue (+6.7%); Las Vegas Strip $8.82B, MGM China $4.02B (+27.6%) record 15.8% share, BetMGM ~$2.4B net revenue competing with Caesars and Las Vegas Sands.
About
MGM Resorts International is a Las Vegas, Nevada-based global gaming, hospitality, and entertainment company — publicly traded on the New York Stock Exchange (NYSE: MGM) as an S&P 500 Consumer Discretionary component — owning and operating a portfolio of destination casino resorts and hotels on the Las Vegas Strip, across the United States in regional markets, and in Macau, China through approximately 55,000 employees. In fiscal year 2024, MGM Resorts reported record consolidated net revenues of $17.24 billion (+6.66% from 2023), the highest annual revenue in company history, with Las Vegas Strip Resorts generating $8.82 billion, Regional Operations generating $3.72 billion, and MGM China contributing $4.02 billion (+27.6% year-over-year) as Macau continued its full recovery from COVID restrictions and market share at MGM China reached an all-time high of 15.8%. CEO Bill Hornbuckle leads MGM's diversified gaming and hospitality strategy across three platforms: Las Vegas (Bellagio, MGM Grand, Aria, Park MGM, Mandalay Bay, New York-New York, Excalibur, Luxor), Regional (Borgata in New Jersey, MGM National Harbor in Maryland, MGM Grand Detroit, MGM Northfield Park in Ohio), and International (MGM Macau and MGM Cotai in China). MGM's BetMGM joint venture (50/50 with UK-based Entain plc) is one of the two largest US online sports betting and iGaming platforms, generating over $2.4 billion in net revenue and approaching profitability as US sports betting regulations expand state by state.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.